. Author manuscript; available in PMC: 2019 Apr 1.

Published in final edited form as: Pediatr Infect Dis J. 2018 Apr;37(4):304–309. doi: 10.1097/INF.0000000000001831

Table 3.

Serologic status, geometric mean antibody titers and timing of serology by HIV status among those fully vaccinated

Vaccine	Immunity				Geometric mean titer			Median days from last vaccine dose

	Serologic immunity¹	N (%)		P-value²			P-value³
	Serologic immunity¹	PHIV	HEU	P-value²	PHIV	HEU	P-value³	PHIV	HEU	p-value³

HBV	Yes	23 (20.9)	17 (37.8)	0.04	76.2	33.9	0.03	882	1255	<0.001
HBV	No	87 (79.1)	28 (62.2)					1221	1290	<0.001

Tetanus⁴	Yes	54 (72.0)	38 (90.5)	0.02	0.42	0.66	0.03	917	956	0.036
Tetanus⁴	No	21 (28.0)	4 (9.5)					716	956	0.10

Hib	Yes	56 (51.4)	33 (68.8)	0.05	4.33	2.85	0.14	954	1066	0.15
Hib	No	53 (48.6)	15 (31.2)					1085	1250	<0.001

Measles	Yes	77 (80.2)	51 (100.0)	<0.001	1.90	6.93	<0.001	1021	1037	0.60
Measles	No	19 (19.8)	0 (0.0)					1045	–	–

Rubella	Yes	70 (72.9)	50 (98.0)	<0.001	52.19	57.8	0.01	1020	1033	0.47
Rubella	No	26 (27.1)	1 (2.0)					1029	1093	0.35

Immunity defined as: hepatitis B surface antibody titer ≥10 IU/L, tetanus antibody titer ≥0.1 IU/mL, Hib antibody titer ≥1.0 μg/mL, measles antibody titer ≥0.120 IU/mL, rubella antibody titer ≥10 IU/mL.

P-values obtained using Fisher’s exact test.

Nonparametric Kruskal-Wallis test.

⁴

One PHIV child missing serologic result for tetanus.